Abstract |
Mutations in the neurofibromatosis type 2 gene (NF2) cause benign nervous system tumors. Common methods for detecting NF2 mutations (such as single stranded conformational polymorphism analysis and denaturing gradient gel electrophoresis) are laborious and time-consuming. We adapted and improved a commercial assay, the Non-Isotopic RNase Cleavage Assay (NIRCAtrade mark, Ambion, Austin, TX) for rapid, non-isotopic, high-sensitivity screening for NF2 mutations in tumors. We improved the assay by: 1) extending the typical NIRCAtrade mark template size of < 500 bp to 1.3 kb without decreasing detection efficiency; 2) modifying the transcription step of the original protocol so that transcription of PCR products was increased by up to 50%; 3) optimizing the combination of cleavage enzymes and reaction time. With these modifications, mutations were found in 15 of 20 patients (75%) using NIRCAtrade mark. Seven of the point mutations detected (two nonsense, two missense, and three splice-site) are novel. All mutations were confirmed by direct sequencing and no mutations were found using direct sequencing in patients that were negative by NIRCAtrade mark. The 75% NF2 mutation detection rate using this design is similar to detection rates in tumors using other mutation detection methods.
|
Authors | R Faudoa, Z Xue, F Lee, M E Baser, G Hung |
Journal | Human mutation
(Hum Mutat)
Vol. 15
Issue 5
Pg. 474-8
( 2000)
ISSN: 1059-7794 [Print] United States |
PMID | 10790209
(Publication Type: Journal Article)
|
Copyright | Copyright 2000 Wiley-Liss, Inc. |
Chemical References |
- Membrane Proteins
- Neoplasm Proteins
- Neurofibromin 2
|
Topics |
- Amino Acid Substitution
- DNA Mutational Analysis
(methods)
- Genes, Neurofibromatosis 2
- Humans
- Introns
- Membrane Proteins
(genetics)
- Mutation
- Mutation, Missense
- Neoplasm Proteins
(genetics)
- Neurofibromatosis 2
(genetics)
- Neurofibromin 2
- Polymorphism, Single-Stranded Conformational
- Sequence Deletion
|